二甲双胍
最大值
医学
药代动力学
药理学
耐受性
置信区间
不利影响
糖尿病
内科学
内分泌学
作者
Yong‐Soon Cho,Shi Hyang Lee,Hyeong-Seok Lim,Kyun‐Seop Bae
标识
DOI:10.3346/jkms.2018.33.e258
摘要
BACKGROUND: In type 2 diabetes mellitus therapy, fixed-dose combination (FDC) can offer not only benefits in glucose control via the combined use of agents, but also increase patient compliance. The aim of this study was to assess the pharmacokinetic equivalence of the high dose of the FDC tablet (gemigliptin/metformin sustained release [SR] 50/1,000 mg) and a corresponding co-administered dose of individual tablets. METHODS: ) of the FDC tablet and co-administration of individual tablet for both gemigliptin and metformin were calculated. RESULTS: for gemigliptin and metformin fell entirely within bounds of 0.800-1.250. Both administration of FDC tablet and co-administration of individual tablets were well tolerated. CONCLUSION: FDC tablet exhibited pharmacokinetic equivalence and comparable safety and tolerability to co-administration of corresponding doses of gemigliptin and metformin XR as individual tablets. Trial registry at ClinicalTrials.gov, NCT02056600.
科研通智能强力驱动
Strongly Powered by AbleSci AI